Olmesartán y enteropatía una década después: una asociación quizá no tan excepcional

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Hipertension y Riesgo Vascular Pub Date : 2022-07-01 DOI:10.1016/j.hipert.2021.12.002
C. Albaladejo Blanco, L. Martínez Capilla, J.A. Martín García
{"title":"Olmesartán y enteropatía una década después: una asociación quizá no tan excepcional","authors":"C. Albaladejo Blanco,&nbsp;L. Martínez Capilla,&nbsp;J.A. Martín García","doi":"10.1016/j.hipert.2021.12.002","DOIUrl":null,"url":null,"abstract":"<div><p>Olmesartan is a potent angiotensin II receptor antagonist commonly used in the treatment of high blood pressure.</p><p>During the last decade, several cases of sprue-like enteropathy have been described associated with the use of this drug - with severe clinical involvement that requires hospitalization - but fortunately with complete remission after its discontinuation.</p><p>We present the case of a multi-pathological 82-year-old woman with a chronic diarrhoeal syndrome that resulted in a weight loss of 20<!--> <!-->kg over the last three months. She was prescribed dual therapy for her hypertension: olmesartan 40<!--> <!-->mg, torasemide 10<!--> <!-->mg, and lercanidipine 10<!--> <!-->mg/day.</p><p>Based on the findings of the patient presented, we conducted a literature search of all the cases published in Spanish indexed journals (PubMed) and compared them, attempting to establish a suspicion profile that would result in the suspension of olmesartan and accelerate the complementary tests necessary to rule out other diagnoses.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183721000878","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

Abstract

Olmesartan is a potent angiotensin II receptor antagonist commonly used in the treatment of high blood pressure.

During the last decade, several cases of sprue-like enteropathy have been described associated with the use of this drug - with severe clinical involvement that requires hospitalization - but fortunately with complete remission after its discontinuation.

We present the case of a multi-pathological 82-year-old woman with a chronic diarrhoeal syndrome that resulted in a weight loss of 20 kg over the last three months. She was prescribed dual therapy for her hypertension: olmesartan 40 mg, torasemide 10 mg, and lercanidipine 10 mg/day.

Based on the findings of the patient presented, we conducted a literature search of all the cases published in Spanish indexed journals (PubMed) and compared them, attempting to establish a suspicion profile that would result in the suspension of olmesartan and accelerate the complementary tests necessary to rule out other diagnoses.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
十年后奥美沙坦和肠病:一个可能不那么特殊的联系
奥美沙坦是一种有效的血管紧张素II受体拮抗剂,通常用于治疗高血压。在过去的十年中,有几例与使用该药有关的云芽样肠病病例被描述-有严重的临床影响,需要住院治疗-但幸运的是,停药后完全缓解。我们目前的情况下,多病理82岁的妇女慢性腹泻综合征,导致体重减轻20公斤,在过去的三个月。她的高血压开了双重治疗:奥美沙坦40毫克,托拉塞米10毫克,莱坎地平10毫克/天。根据该患者的研究结果,我们对发表在西班牙语索引期刊(PubMed)上的所有病例进行了文献检索并进行了比较,试图建立一个可能导致暂停使用奥美沙坦的怀疑档案,并加快必要的补充测试以排除其他诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hipertension y Riesgo Vascular
Hipertension y Riesgo Vascular Medicine-Internal Medicine
CiteScore
1.70
自引率
16.70%
发文量
38
审稿时长
39 days
期刊介绍: La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.
期刊最新文献
Air pollution and stroke: It's time to act Effect of air pollutants on ambulatory blood pressure Albuminuria and cardiovascular risk Impacto pronóstico de los factores de riesgo cardiovascular en pacientes ingresados por síndrome coronario agudo Importancia de la hipertensión en pacientes con primer episodio de ictus isquémico: estudio retrospectivo de 20 años
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1